Unknown

Dataset Information

0

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.


ABSTRACT: The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-β1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-β1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-β1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-β1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.

SUBMITTER: Uher T 

PROVIDER: S-EPMC5282956 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher Tomas T   Uher Tomas T   Fellows Kelly K   Horakova Dana D   Zivadinov Robert R   Vaneckova Manuela M   Sobisek Lukas L   Tyblova Michaela M   Seidl Zdenek Z   Krasensky Jan J   Bergsland Niels N   Weinstock-Guttman Bianca B   Havrdova Eva E   Ramanathan Murali M  

Journal of lipid research 20161206 2


The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β)1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL  ...[more]

Similar Datasets

| S-EPMC6381428 | biostudies-literature
| S-EPMC7170219 | biostudies-literature
| S-EPMC6694336 | biostudies-literature
| S-EPMC10412752 | biostudies-literature
| S-EPMC7380268 | biostudies-literature
| S-EPMC8260657 | biostudies-literature
| S-EPMC4824021 | biostudies-literature
| S-EPMC9849374 | biostudies-literature
2019-11-08 | GSE140106 | GEO
| S-EPMC9224825 | biostudies-literature